Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (539)	5/15/1999 10:51:00 AM
From: Dr. John M. de Castro	Respond to of 1494

I found the $200,000 Merz loan interesting. It was made against up-front payments from a partnership. Merz is a very conservative company. They would not make this loan unless they were darn sure that the partnership was was in the bag. It should be an exciting month coming up :-) John de C

To: BRAVEHEART who wrote (539)	5/17/1999 1:57:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

memantine for reperfusion-induced arrhythmias, a completely new use for this incredibly useful drug. john de C Eur J Pharmacol 1999 Feb 5;366(2-3):167-74 Arrhythmias induced by myocardial ischaemia-reperfusion are sensitive to ionotropic excitatory amino acid receptor antagonists. D'Amico M, Di Filippo C, Rossi F, Rossi F Institute of Pharmacology and Toxicology, Faculty of Medicine and Surgery, 2nd University of Naples, Italy. We have investigated the effects of +)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK801), a non-competitive N-methyl-D-aspartate (NMDA) ionotropic excitatory amino acid receptor antagonist, and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), a non-NMDA ionotropic excitatory amino acid receptor antagonist, ketamine and memantine, NMDA receptor channel blockers, on ventricular arrhythmias induced by myocardial ischaemia and myocardial ischaemia-reperfusion. Coronary artery occlusion caused 100 +/- 2% ventricular tachycardia, in saline treated group, and 60 +/- 3% ventricular fibrillation. 66 +/- 6% of the animals recovered from ventricular fibrillation, while in 34 +/- 4% of animals the ventricular fibrillation caused mortality. The incidence of ventricular tachycardia, ventricular fibrillation and mortality was not modified by treatment of rats with MK801 (0.3 mg/kg i.v.), CNQX (1 mg/kg i.v.), ketamine (10 mg/kg) and memantine (1.5 mg/kg), injected 5 min prior to occlusion. Reperfusion caused severe arrhythmias which started within 5 +/- 2 s. For instance, in the saline treated group, the incidence of ventricular tachycardia was 100 +/- 5%, while ventricular fibrillation occurred in 87 +/- 3% of the animals and lasted 90 +/- 12 s. The mortality was 62 +/- 6%. The incidence of ventricular tachycardia, ventricular fibrillation and mortality induced by reperfusion was greatly (P < 0.01) reduced in animals treated with MK801 (0.3 mg/kg i.v.), CNQX (1 mg/kg i.v.), ketamine (10 mg/kg) and memantine (1.5 mg/kg), injected 5 min prior to occlusion. Therefore, reperfusion-induced arrhythmias, but not ischaemia-induced arrhythmias, are sensitive to NMDA/non-NMDA ionotropic excitatory amino acid receptor antagonists.

To: BRAVEHEART who wrote (539)	5/17/1999 2:09:00 PM
From: Dr. John M. de Castro	Respond to of 1494

More evidence suggesting Xerecept usefulness in preventing edema. John de C Microsurgery 1998;18(2):76-8 Reduction of reperfusion injury edema with corticotropin-releasing factor (CRF): a pilot study. Whitney TM, Bentz ML, Johnson PC Division of Plastic and Reconstructive Surgery, Lahey Hitchcock Clinic, Burlington, MA 01805, USA. Regulation of capillary permeability with ischemic reperfusion injury is a complex interaction between vascular endothelium and circulating blood factors. Corticotropin-releasing factor (CRF), a 41 -amino acid peptide CNS neurotransmitter known to modulate the pituitary-adrenal axis during stress response, has been shown to affect capillary leakage after thermal injury in peripheral tissue. When administered prior to ischemic reperfusion injury in a pedicled rat hindlimb model, CRF (80 mcg/kg) reduced limb weight gain to approximately 50% of saline control, suggesting a role for CRF in control of vascular permeability. The characteristics of CRF are reviewed.